LB Pharmaceuticals grants equity awards to new executives as it advances LB-102 toward Phase 3 trials in schizophrenia.
Quiver AI Summary
LB Pharmaceuticals Inc announced the granting of equity awards to its new Senior Vice Presidents, Ellen Rose and Lindsay Beaupre, as an inducement for their employment with the company. These awards, made under Nasdaq Listing Rule 5635(c)(4), included options for 100,000 shares for Rose and 75,000 shares for Beaupre at an exercise price of $20.73 per share. The options have a ten-year term and will vest over four years. Additionally, LB Pharmaceuticals is advancing its clinical candidate LB-102, which has shown promise in treating acute schizophrenia and is preparing for Phase 3 trials, following positive Phase 2 results. The company is focused on developing innovative therapies for neuropsychiatric disorders, positioning LB-102 as a potential key treatment option in the field.
Potential Positives
- The appointment of Ellen Rose and Lindsay Beaupre as Senior Vice Presidents, along with their significant equity awards, highlights the company's commitment to attracting top talent in leadership roles.
- The grant of options linked to LB Pharmaceuticals' stock may align the interests of these new executives with those of shareholders, potentially driving company performance and shareholder value.
- LB-102's advancement into Phase 3 clinical trials signifies a critical step forward for the company’s lead product candidate, with the potential for it to address significant unmet needs in psychiatric care.
- The positive outcomes from the Phase 2 trial of LB-102, demonstrating efficacy in treating acute schizophrenia, bolster the company's prospects and validate its research and development efforts.
Potential Negatives
- Granting significant equity awards to new executives may raise concerns about compensation practices, particularly in terms of potential misalignment with shareholder interests during a phase of clinical development.
- The reliance on an "inducement grant" could be seen as indicative of potential difficulties in attracting top talent without offering substantial incentives, raising questions about the company's appeal as an employer in a competitive market.
- While advancing LB-102 into Phase 3 trials, there remains uncertainty over the drug's ultimate approval and market success, which could impact the company's financial stability and investor confidence.
FAQ
What is the recent equity award announcement by LB Pharmaceuticals?
LB Pharmaceuticals announced equity awards to new executives Ellen Rose and Lindsay Beaupre as part of their employment inducement.
Who are the new executives at LB Pharmaceuticals?
Ellen Rose is the Senior VP of Corporate Affairs, and Lindsay Beaupre is the Senior VP of People and Culture.
What is LB-102, and what are its clinical trial statuses?
LB-102 is a Phase 3-ready drug for acute schizophrenia, advancing to Phase 3 trials after positive Phase 2 results.
What are the potential applications for LB-102?
LB-102 may also be developed for conditions like bipolar depression, major depressive disorder, and Alzheimer's disease psychosis.
How does LB Pharmaceuticals position its product LB-102 in the market?
LB Pharmaceuticals aims for LB-102 to become a leading antipsychotic treatment option in the U.S. for various neuropsychiatric disorders.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$LBRX Insider Trading Activity
$LBRX insiders have traded $LBRX stock on the open market 6 times in the past 6 months. Of those trades, 6 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $LBRX stock by insiders over the last 6 months:
- TRACK BIOTECHNOLOGY MASTER FUND, LTD. DEEP has made 2 purchases buying 2,666,666 shares for an estimated $39,999,990 and 0 sales.
- RAN NUSSBAUM purchased 1,000,000 shares for an estimated $15,000,000
- MANAGEMENT 4 G.P. (2015) LTD. PONTIFAX purchased 1,000,000 shares for an estimated $15,000,000
- VENTURES GP III, L.L.C. VIDA has made 2 purchases buying 333,333 shares for an estimated $4,999,995 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$LBRX Hedge Fund Activity
We have seen 55 institutional investors add shares of $LBRX stock to their portfolio, and 0 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DEEP TRACK CAPITAL, LP added 3,352,804 shares (+inf%) to their portfolio in Q3 2025, for an estimated $52,940,775
- RA CAPITAL MANAGEMENT, L.P. added 1,776,958 shares (+inf%) to their portfolio in Q3 2025, for an estimated $28,058,166
- TCG CROSSOVER MANAGEMENT, LLC added 1,745,016 shares (+inf%) to their portfolio in Q3 2025, for an estimated $27,553,802
- COMMODORE CAPITAL LP added 1,500,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $23,685,000
- LOGOS GLOBAL MANAGEMENT LP added 1,130,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $17,842,700
- JPMORGAN CHASE & CO added 1,032,603 shares (+inf%) to their portfolio in Q3 2025, for an estimated $16,304,801
- BLACKROCK, INC. added 975,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $15,395,250
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$LBRX Analyst Ratings
Wall Street analysts have issued reports on $LBRX in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Stifel issued a "Buy" rating on 12/11/2025
- Piper Sandler issued a "Overweight" rating on 10/06/2025
- Leerink Partners issued a "Outperform" rating on 10/06/2025
To track analyst ratings and price targets for $LBRX, check out Quiver Quantitative's $LBRX forecast page.
$LBRX Price Targets
Multiple analysts have issued price targets for $LBRX recently. We have seen 3 analysts offer price targets for $LBRX in the last 6 months, with a median target of $35.0.
Here are some recent targets:
- Paul Matteis from Stifel set a target price of $35.0 on 12/11/2025
- Yasmeen Rahimi from Piper Sandler set a target price of $78.0 on 10/06/2025
- Marc Goodman from Leerink Partners set a target price of $34.0 on 10/06/2025
Full Release
NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced that it has granted to Ellen Rose, the new Senior Vice President, Corporate Affairs and Lindsay Beaupre, the new Senior Vice President of People and Culture of LB Pharmaceuticals, equity awards outside of, but subject to the terms and conditions of, the LB Pharmaceuticals Inc 2025 Equity Incentive Plan. The equity award was granted on January 9, 2026, pursuant to the “inducement grant” exception provided under Nasdaq Listing Rule 5635(c)(4) as an inducement material to Ms. Rose and Ms. Beaupre entering into employment with LB Pharmaceuticals.
Ms. Rose and Ms. Beaupre received options to purchase 100,000 and 75,000 shares of LB Pharmaceuticals’ common stock, respectively. The options carry a ten-year term and an exercise price per share equal to $20.73, which was the closing price of LB Pharmaceuticals’ common stock on the date of grant, and vests over 4 years, with 25% of the shares underlying the options vesting on the first anniversary of the grant date and an additional 1/48 th of the shares vesting monthly thereafter, subject to continuous service through the applicable vesting dates.
About LB-102
LB-102 is a Phase 3-ready oral, small molecule and a methylated derivative of amisulpride. In early 2025, LB Pharmaceuticals announced positive data from a four-week placebo-controlled, double-blinded, Phase 2 trial in patients with acute schizophrenia. The Phase 2 trial demonstrated statistically significant benefit versus placebo at all doses studied, a potentially class leading safety profile among D2 antagonists and partial agonists, and positive effects on negative symptoms and cognition. LB-102 is advancing into a Phase 3 clinical trial for acute schizophrenia and a Phase 2 clinical trial for bipolar depression. Additional expansion opportunities for LB-102 could include major depressive disorder (MDD), predominantly negative symptoms of schizophrenia, Alzheimer’s disease psychosis and agitation, as well as bipolar mania and cognitive impairment associated with schizophrenia.
About LB Pharmaceuticals
LB Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the Company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102, if approved, has the potential to become a mainstay of psychiatric practice by offering a potentially attractive alternative to branded and generic therapeutics for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases.
Media and Investor Contact
Ellen Rose
[email protected]
